Immunity

Induction of broadly neutralizing antibody (bnAb) responses remains a central challenge to designing efficacious HIV vaccines. Lineage design strategies, in which bnAb precursors are guided via iterative immunizations to their mature forms, depend on high levels of somatic mutation and the recall of antigen-specific B cells. Recent studies have identified spatial context as an important determinant of boosting efficacy, but the application of this to HIV vaccines and the underlying mechanisms are incompletely understood. Here, using mice harboring a V3-glycan bnAb lineage precursor knock-in combined with lineage-tracing and single-cell analyses, we show that persistent germinal centers (GCs) support continued affinity maturation of founder clones and ipsilateral boosting preferentially engages these lineages in secondary GCs. In contrast, contralateral boosting predominantly recruits naive B cells and memory B cells not directed towards the immunizing antigen. The few memory cells recruited at this site were biased towards a plasma cell fate. Finally, we identify disfavored mutational trajectories within the V3-glycan bnAb lineage, revealing intrinsic constraints on bnAb lineage evolution.

While aging is the primary risk factor for cancer development and a critical driver of metastasis, yet how aging selectively remodels specific distant organs to favor tumor colonization remains unclear. Here, we demonstrate that host aging selectively enhances susceptibility to lung metastasis in an inflammation-dependent manner, without uniformly affecting other organs. Single-cell RNA sequencing reveals that the aged lung accumulates PD-L1CTLA-4IgMIgD- regulatory B (Breg)-like cells, representing the immune population most amplified by the cooperative effects of aging and tumor burden. Trajectory analysis delineates their differentiation from naive B cells, driven by Il10, Ctla4, Cd274, and Egr1 upregulation. This program is evolutionarily conserved, increasing progressively with human chronological lung age. Mechanistically, aged CD140a adventitial fibroblasts drive CXCL13-dependent B-cell reprogramming into a senescent state. These Breg-like cells directly impair natural killer cell cytotoxicity and CD4 T-cell responses, accelerating pulmonary colonization. Our findings reveal a targetable, lung-specific age-associated stromal-immune axis driving metastatic organotropism.

Personalized neoantigen (neoAg) vaccines have shown clinical promise in solid tumors1-8, yet their efficacy and mechanism of action in hematopoietic malignancies remain poorly defined9-11. Herein, we establish an immunocompetent syngeneic A20 B-cell lymphoma platform to test the efficacy of neoAg vaccines used either as mono- or combinatorial therapies with other immunotherapies12-17. Whereas subcutaneous A20 tumors were refractory to single-agent PD-1 or CTLA4 therapy, they were eradicated in a T cell-dependent manner in 90% of syngeneic hosts treated with dual immune checkpoint therapy (dual ICT, i.e., PD-1 + CTLA4). By mapping antigen specificity of dual-ICT-elicited T cells, we identified and validated dominant endogenous A20 MHC-I and MHC-II neoantigens and designed therapeutic synthetic long peptide (SLP) vaccines containing these neoepitopes. This vaccine (A20 neoVAX) promoted robust neoAg-specific CD4{square} and CD8{square} T cell responses in naive syngeneic BALB/c mice and induced tumor rejection in [~]70% of subcutaneous tumor-bearing mice. In addition, nearly all mice rejected their subcutaneous A20 tumors when A20 neoVAX was combined with PD-1. To render the results of this study more physiologic, we developed a systemic A20 lymphoma model and found that dual ICT failed to control tumor progression and A20 neoVAX delayed tumor progression and prolonged animal survival but did not induce tumor rejection. In contrast, A20 neoVAX plus dual ICT achieved durable systemic tumor elimination. Mechanistically, the combination of A20 neoVAX plus dual ICT amplified priming of A20 neoAg-specific T cells, prevented T cell dysfunction, sustained the cytotoxic capacity of tumor-specific CD8+ T cells, and induced Th1-skewing of CD4+ T cells in tumor and peripheral compartments. To increase the clinical relevance of these findings and to minimize potential adverse events in tumor-bearing, therapeutically treated individuals, we substituted CD8-targeted cytokine muteins (CD8-IL2 or CD8-IL21) for CTLA4. These agents represent genetically modified forms of IL-2 or IL-21 that selectively stimulate CD8+ T cells but have significantly reduced capacity to activate chronic inflammation and immunosuppressive functions of other immune cells. Whereas mice bearing systemic A20 lymphoma treated with either nothing, A20 neoVAX, or A20 neoVAX + CD8-IL2 failed to control tumor outgrowth, 66.7% of tumor-bearing mice treated with A20 neoVAX + CD8-IL2 + PD-1 rejected their tumors. In similar experiments in which CD8-IL21 was substituted for CD8-IL2, tumor clearance was also observed in two-thirds of A20-bearing mice but now rejection occurred in the absence of PD1. Together, these data define a framework for optimal personalized neoAg vaccination in B-lymphoma and demonstrate that neoAg vaccines can safely synergize with CD8+ T cell-selective immunotherapies to prevent T-cell dysfunction and generate durable systemic anti-tumor immunity.

Tissue-resident memory B cells (BRM) provide powerful localized protection against microbial infection in barrier tissues. It is unknown if analogous BRM populations survey solid tumors and contribute to anti-cancer immunity. We profiled B cells from patients with colorectal cancer and cutaneous basal cell carcinoma and identified a CD69+ memory B cell population consistent with a tissue-resident phenotype. Integrative analysis of transcriptomic datasets identified an optimized signature enriched across cancer types. Tumor infiltrating BRM-like cells preferentially exhibited autoreactivity and their signature correlated with patient outcomes and response to immunotherapy. Skin and lung targeted vaccination established localized BRM that provided IgA dependent organ specific protection upon tumor challenge in murine models. These findings establish BRM as an active component of anti-cancer immunity via preferential reactivity to tumor associated self-antigens.

The theoretical diversity of T cell receptors (TCRs), generated through V(D)J recombination, is enormous, yet the diversity of TCRs capable of recognizing the same epitope remains unknown. Defining this TCR solution space is essential for uncovering basic principles that govern TCR specificity. Using single-cell RNA and TCR sequencing, we generated ultra-deep (more than 4000 unique TCRs per epitope) epitope-specific TCR libraries derived from 560 immunized C57BL/6 mice, identifying over 27,000 unique epitope-reactive TCRs across three distinct CD8+ T cell epitopes presented by two major histocompatibility complex (MHC) class I alleles. Saturation analyses indicated that the solution space for all studied epitopes comprises many tens of thousands of unique TCRs. Despite highly skewed and peptide-dependent VJ-usage patterns, nearly the entire set of functional germline V/ and J/ segments was detected at least once within each epitope-specific repertoire. Therefore, diversity of epitope-specific TCRs is not limited by distinct germline combinations but rather can emerge from a near-to-complete combinatorial space of - and -chain, V and J segments paired with compatible CDR3 sequences.

Shingles (herpes zoster), caused by reactivation of varicella zoster virus (VZV), affects approximately one third of the global population. Besides environmental factors, host genetics play a role in determining susceptibility to shingles. Here, we performed a large-scale genome-wide association study (GWAS) meta-analysis of shingles across five cohorts comprising 72,935 cases and 1,644,597 controls of European ancestry. We identified seven genome-wide significant loci, including novel associations at IGHG1, IFNAR2, MPV17L2 (IL12RB1), BACH2, and RHOBTB1, implicating MHC class I antigen presentation, type I interferon signaling, humoral immunity, and T-cell memory maintenance as key genetic determinants of shingles susceptibility. HLA fine-mapping identified eight independently associated HLA alleles, mapping predominantly to HLA-B (HLA-B*44:02), with additional associations at HLA-C (HLA-C*02:02) and an independent association at HLA-DQB1 (HLA-DQB1*05:02). Gene set analysis and stratified LD score regression identified significant enrichment of shingles heritability in immune tissues and pathways. Phenome-wide association study, genetic correlation analysis, and bidirectional two-sample Mendelian randomization identified causal effects of shingles on stroke, herpes simplex infection, and systemic lupus erythematosus, and suggested pain conditions and arthrosis as risk factors for shingles. These findings advance understanding of the genetic architecture of VZV reactivation and its causal relationships with other diseases.

Natural SARS-CoV-2 infections or vaccinations induce neutralizing antibodies (nAbs) offer protection from severe disease. The shared use of IGHV3-53/3-66 genes makes this class of monoclonal antibodies (mAbs) a public clonotype and is well established, but the evolution and structural basis of how these public antibodies maintain broad binding and acquire potent neutralizing activity is not completely understood. To understand how these features are facilitated by the IGHV3-53/3-66 germline segments and enhanced by somatic mutations, we investigated the biology of a panel of 242 human mAbs isolated from an individual infected with SARS-CoV-2 BA.1 strain and recovered. Interestingly, a mAb designated COV2-3731 encoded by IGHV3-53/IGKV1-33 retained potent neutralizing activity against SARS-CoV-2 variants BA.2.86, JN.1, KP.2, BA.3.2, and, to some extent, KP.3. Studies using deep mutational scanning with a BA.2 lentiviral library and determination of the structural complex of the BA.2 S protein and COV2-3731 Fab fragments using cryo-EM revealed key contact residues. Further, germline revertant analysis of the COV2-3731 mAb provided additional insights into how this COV2-3731 and other IGHV3-53/3-66-encoded public antibodies evolve to gain breadth against antigenically distinct SARS-CoV-2 variants such as BA.2.86, JN.1, KP.2, and BA.3.2.

Interactions between Human Leukocyte Antigen (HLA) molecules and their cognate immunoreceptors are essential for regulating innate and adaptive immune cell functions. Leukocyte Immunoglobulin-like Receptors (LILRs) are key regulators of HLA-mediated immune responses, owing to their broad expression across immune cell populations and their ability to modulate both immune activation and tolerance. Among these, LILRB1-HLA interactions are increasingly recognised as important in transplantation, chronic infection and cancer therapies. Unlike other HLA-binding receptors, which recognise epitopes specific to HLA subsets, LILRB1 primarily engages the relatively conserved 3 and {beta}2-microglobulin components of HLA molecules, supporting its role as a broad regulator of pan-HLA class I-mediated functions. Nonetheless, there have been conflicting findings regarding the breadth of LILRB1-HLA-I interactions. While direct affinity studies on a limited subset of HLA-I molecules have revealed no significant differences in LILRB1 binding, broader analyses using single-antigen bead arrays suggest underlying variability. Here, we show through a broad binding assay that, while LILRB1 is a broad HLA-I-binding receptor, it exhibits differential preferences across HLA-I allotypes. Molecular dynamics analyses of the HLA-I-LILRB1 interface suggest that HLA-3 domain dynamism underlies these binding differences. We further determined the crystal structure of LILRB1 and used it to highlight intrinsic structural flexibility within its domains. Finally, these structural insights were leveraged to refine our understanding of the binding modalities of therapeutic monoclonal antibodies currently described. Together, our findings establish structural and mechanistic bases for differential HLA-I recognition by LILRB1 and provide insights into immunotherapeutic targeting of LILRB1.

Aberrantly elevated cell-surface sialylation, or hypersialylation, is a common feature of human cancers and contributes to immune evasion. Sialidase-based therapies have therefore emerged as a strategy to disrupt this glyco-checkpoint. Although the immunosuppressive role of tumor-associated sialylation is well established, how sialylation on human T cells shapes anti-tumor responses remains poorly defined. Here, we identify surface sialoglycans on T cells, particularly 2,3-linked structures, as a cell-intrinsic restraint on human T cell activation, proliferation, and effector function. In vitro, enzymatic desialylation enhanced T cell activation, proliferation, cytokine production, and bispecific T cell engager (TCE)-mediated tumor-cell killing in healthy donor PBMC co-cultures. In ex vivo cultures of primary chronic lymphocytic leukemia (CLL) PBMCs, sialidase treatment combined with the CD20-directed TCE glofitamab enhanced cytotoxic effector transcriptional programming in autologous T cells. Single-cell RNA sequencing combined with lectin-based CITE-seq linked treatment-induced transcriptional states to lectin-defined cell-surface glycan signatures within the same single-cell dataset. This integrated analysis revealed that naive and, to a lesser extent, central memory T cells combined elevated baseline 2,3-sialylation signatures with the clearest transcriptional responses to glofitamab plus sialidase treatment. CD43 emerged as a major carrier of 2,3-linked sialoglycans, and its deletion attenuated sialidase-enhanced T cell activation. Together, these findings identify sialylation of the T cell surface as a subset-specific restraint on human TCE responses and provide a rationale for testing sialidase-TCE combinations designed to engage less-differentiated T cell populations. One-sentence summaryDesialylation enhances bispecific T cell engager responses by relieving a sialoglycan-dependent restraint in human T cells.

The generation of an effective T cell response against an antigen depends on the recognition of the antigen by the T cell receptor (TCR), followed by T cell priming, initiating coordinated biophysical, biochemical and proliferative changes that drive differentiation into effector and memory clones. The immunological environments in which priming occurs, such as natural infection or vaccination, influences the quality and persistence of memory T cells, but the long-term impacts remain incompletely understood. Here, we investigate how the mode of priming shapes durable antigen-specific CD4+ T cell memory, utilising two cohorts 3-4 years after initial antigen encounter: individuals recovered from SARS-CoV-2 infection and infection-naive individuals who received a SARS-CoV-2 vaccination. Using ex vivo single-cell RNA sequencing, paired TCR sequencing and in vitro functional analyses, we characterise the transcriptional, clonal and functional profile of Spike-specific CD4+ T cells. Across both cohorts, CD4+ T cell responses against spike epitopes S166-180, S751-765 and S866-880, were immunodominant, with shared public TCR clonotypes indicating conserved antigen-recognition regardless of mode of priming. Despite this shared specificity, infection-primed individuals exhibited greater TCR repertoire diversity and lower CDR3{beta} sequence convergence. Transcriptionally, infection-primed cells exhibited a more cytotoxic and effector phenotype, while vaccine-primed cells preferentially adopted T follicular helper (Tfh)- and Th1-associated phenotypes. Infection-primed individuals also displayed enrichment of cell adhesion and integrin signalling pathways, with a greater proportion of spike-specific CD4+ T cells expressing 4{beta}1 integrin subunits, consistent with enhanced migratory and effector potential. Collectively, our findings demonstrate that the mode of antigen priming may influence the long-term CD4+ T cell memory states, influencing TCR repertoire diversity, functional differentiation and tissue-homing potential, years after the initial immune response.

Maternal immune transfer is essential for early-life health, yet whether immune experiences before pregnancy shape maternal physiology to optimize immunity in subsequent offspring is unclear. Here, we show that respiratory viral infection before pregnancy confers robust protection against lethal neonatal influenza through antibodies transferred postpartum in milk. Despite the predominance of IgA in milk, antiviral IgG is indispensable for protection. Pregnancy amplifies pre-existing antiviral B cell responses, while prior infection durably reprograms the mammary gland to promote transfer of circulating antiviral IgG into milk. These antibodies retain their epitope specificity, are enriched for broadly protective influenza epitopes, remain functional after passage through the neonatal intestine, and enter offspring circulation through FcRn to provide protection beyond weaning. Natural transmission of virus from infected offspring to mothers establishes maternal immunity that protects future offspring, revealing a coordinated adaptive program that links maternal immune history, pregnancy, and lactation to optimize intergenerational immunity. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=178 SRC="FIGDIR/small/744935v1_ufig1.gif" ALT="Figure 1"> View larger version (66K): org.highwire.dtl.DTLVardef@1f82cbeorg.highwire.dtl.DTLVardef@41ac81org.highwire.dtl.DTLVardef@1a4538aorg.highwire.dtl.DTLVardef@168bc21_HPS_FORMAT_FIGEXP M_FIG O_FLOATNOGRAPHICAL ABSTRACTC_FLOATNO C_FIG HIGHLIGHTSO_LIPreconceptual maternal intranasal influenza infection confers complete neonatal B cell mediated protection against lethal neonatal influenza infection that persists beyond weaning into early adulthood. C_LIO_LIProtection can be transmitted postnatally through milk and is fully dependent on maternal IgG. C_LIO_LIPregnancy enhances rather than suppresses antiviral B cell programs in the mother. C_LIO_LIMilk IgG targets a restricted set of conserved influenza Hemagglutinin epitopes, suggesting selective transfer of broadly protective antibody populations. C_LIO_LIProtective IgG in milk derives from maternal circulation, not from local B cell mammary gland production. C_LIO_LIRespiratory infection before pregnancy induces long-lived vascular, stromal, and epithelial transcriptional remodeling of the mammary gland. C_LIO_LINeonatal Fc Receptor (FcRn) mediated transport of milk IgG into circulation is required for protection. C_LIO_LIInfected neonates transmit virus back to mothers, extending protection to subsequent litters for multi-generation protection. C_LI

Tumor-draining lymph nodes serve as critical sites for the generation, maintenance and differentiation of stem-like CD8 T cells during antitumor immune responses. Recent evidence has shown that delivering interleukin-2 to PD1 stem-like CD8 T cells using PD1-IL2v, an immunocytokine combining PD-1 blockade and IL-2R agonism, promotes their differentiation into potent effector cells with enhanced tumor-killing capacity. However, it remains unclear how targeted interleukin-2 therapies imprint early stem-like T-cell differentiation programs. Here, using single-cell transcriptomics and T-cell receptor sequencing in murine pancreatic tumor models, we demonstrate that PD1-IL2v induces an early bifurcation in the differentiation of stem-like CD8 T cells within tumor-draining lymph nodes. We identify an effector-primed stem-like population characterized by the expression of interferon-response genes, natural killer cell receptor genes, and Cx3cr1, consistent with activation of interleukin-2 and STAT5-associated programs. Clonal tracking revealed substantial overlap between these lymph node-derived cells and intratumoral effector populations, supporting a developmental relationship between early priming in lymph nodes and downstream effector differentiation. In contrast, an alternative stem-like state that displayed features associated with T-cell exhaustion, including increased Tox expression, was observed upon PD-1 therapy. Together, these findings identify an early branch point in stem-like T-cell differentiation and provide mechanistic insight into how PD1-IL2v circumvents exhaustion pathways to preferentially generate functional antitumor immunity.

The majority of mortality during viral infections occurs in older males; however, underlying mechanisms by which age and sex shape antiviral immunity and pathological inflammatory responses remain incompletely understood. Here, we performed time-resolved single-cell RNA sequencing across 16 conditions spanning age, sex, and four stages of influenza infection in mice, generating a high-resolution atlas. Aged mice demonstrate delayed antiviral and inflammatory responses in multiple myeloid cells, impairing viral clearance, which delays recovery. Similarly, endothelial cells from aging mice show prolonged inflammatory and antiviral gene signatures. Altered gene signatures in immune and endothelial cells result in a shift in endothelial-immune interactions in the aged lung. Further, the infection status of the cell is a major driver of transcriptional state, with infected myeloid cells exhibiting broad upregulation of genes, including interferon-stimulated, inflammatory, complement, and oxidative stress-related genes. To assess whether these age-associated transcriptional patterns are conserved in humans, we examined BAL cells obtained from healthy individuals and COVID-19 patients, and found that immune cells from aged COVID-19 patients had elevated antiviral and pro-inflammatory gene expression compared to cells from young patients. Our analyses of sex differences identified that multiple myeloid cell types in aged male mice, but not in young male mice, show persistent inflammatory responses at later stages of infection, a likely mechanism contributing to elevated mortality in older males. These data reveal how infection status of the cell, age, and sex interact to drive persistent inflammation and impaired resolution, providing a foundational resource for designing age- and sex-specific therapeutic strategies.

The limited mechanistic understanding of Human Cytomegalovirus (HCMV) infection and neutralization has hindered the effective application of antibodies for HCMV prevention and therapy. To address this, we conducted high-resolution cryo-EM analysis of 17 human monoclonal antibodies targeting HCMV glycoproteins gH and gL. This analysis revealed a landscape of vulnerable epitopes, including detailed binding modes, spatial orientations, and structural features associated with distinct neutralization phenotypes. By comprehensively characterizing the neutralizing properties of these antibodies and their combinations, we identified synergistic antibody cocktails that enhance the neutralization capacity of individual antibodies. Notably, while single antibodies only partially neutralized HCMV, their synergistic combinations achieved substantially more complete inhibition. Together, these findings delineate structural correlates of HCMV neutralization and establish functional principles for antibody-based combinatorial targeting of HCMV.

Epstein-Barr virus (EBV) reprograms B cells in autoimmune disease. Reprogrammed EBV+ B cells activate nearby B and CD4+ T cells, via upregulated antigen presentation and costimulatory machinery, to drive autoimmune pathology. EBV reactivation is a known correlate of long COVID, which is a heterogeneous condition that can bear similarities to autoimmune disease. However, the mechanisms underpinning this association remain unresolved. We report on EBV metabolically reprogrammed B cells in patients with COVID-19. We find EBV+ B cells provide stimulatory signals to bystander B and CD4+ T cells. SARS-CoV-2 infected participants exhibiting elevated fractions of EBV+ B cells present, at convalescence, with dysregulated lipid profiles, increased autoantibody titers, and post-acute symptomology likely reflective of this metabolic reprogramming and cell-cell interactions. Enrichment of our EBV+ B cell signatures seen in patients with COVID-19 is similar in patients with lupus and multiple sclerosis suggesting a potentially shared pathway of EBV-driven dysfunction across diseases.

CD4+ T cells recognize antigens from microbiota, diet, and pathogens via T cell receptors (TCRs) and orchestrate immunity by differentiating into tolerogenic regulatory (Treg) or pro-inflammatory effector (Teff) lineages (e.g. TH1 or TH17) (1). Dysregulation of these responses underlies numerous gastrointestinal inflammatory and infectious diseases (2-6). The prevailing paradigm suggests that individual microbes and dietary antigens drive distinct cell fates (e.g., segmented filamentous bacteria [SFB] induce TH17 cells (7) whereas Helicobacter hepaticus (8) and diet (9) induce Tregs). However, the generality of this model is uncertain: several key organisms are atypical, and foundational studies often omitted a complex microbiome or a diverse polyclonal TCR repertoire. Here we develop a high-throughput pipeline to screen hundreds of TCRs from mice colonized from birth with a 116-strain human microbiota (hCom2v), demonstrating that TCRs recognizing microbiota or dietary antigens are overwhelmingly enriched in the induced Treg (iTreg) lineage. Endogenous CD4+ T cells specific for these antigens adopt a uniform iTreg phenotype in vivo, both in hCom2v-colonized and conventional mice. This baseline tolerance is robust to acute inflammation but breaks down following a 'two-hit' combination of inflammation and genetic susceptibility, allowing Teff to emerge against otherwise Treg-restricted antigens. These data support a revised paradigm in which antigen-specific Treg induction is the default response to foreign antigens in the healthy gut, and effector responses are an exception reflecting a perceived threat. Reframing gastrointestinal immunity as a tolerance-first system provides a framework for understanding inflammatory disease pathogenesis and suggests that therapeutic strategies should aim to restore a Treg-predominant baseline.

Regulatory T (Treg) cells expressing ROR{gamma}t accumulate in the intestinal mucosa, yet the signals that determine whether they remain suppressive or acquire inflammatory features are incompletely defined. We first reanalyzed human ileal single-cell data and identified Crohns disease-enriched FOXP3 states in which RORC, HIF1A, hypoxia-responsive, inflammatory, and metabolic programs converged. We then deleted Hif1a in ROR{gamma}t-expressing cells and tested acute DSS colitis, T cell transfer colitis, and azoxymethane/DSS-induced colitis-associated colorectal cancer (CAC). {Delta}Hif1a mice were protected in all three settings. In lymphopenic recipients given the same pathogenic naive T cells, changing only the genotype of the cotransferred Treg population enhanced protection, linking the phenotype to regulatory-cell function in vivo. Reanalysis of mouse colonic Treg single-cell ATAC-seq nominated suppressive and mitochondrial programs for cell-intrinsic testing during low HIF1- expression. {Delta}Hif1a ROR{gamma}t Treg produced more IL-10 and less IL-17A and IFN-{gamma}, limited responder-cell proliferation, contained fewer dysfunctional and mitochondrial-reactive-oxygen-species-high mitochondria, favored fusion-associated transcription, and displayed greater basal and maximal oxygen consumption and reserve capacity. During CAC, HIF-1 loss blunted inflammatory ROR{gamma}t Treg accumulation and reduced tumor burden. Human trajectory and gene-regulatory-network analyses further predicted that HIF1A perturbation would oppose selected disease-associated branches. Together, these findings identify HIF-1 as a context-dependent checkpoint that connects hypoxia-responsive transcription to mitochondrial fitness and inflammatory plasticity in intestinal ROR{gamma}t Treg.

Ulcerative colitis (UC) is characterised by chronic colonic inflammation with marked heterogeneity in disease severity and therapeutic outcomes. Here, we define a spatially organised, polyfunctional cytotoxic CD4 T-cell state associated with mucosal inflammation and adverse therapeutic outcomes in UC. Integrating ex vivo T-cell receptor stimulation with multi-cohort bulk and single-cell transcriptomics and multiparameter flow cytometry, we show that GZMB CD4 T cells are preferentially enriched in inflamed UC mucosa, but not peripheral blood, and co-express cytotoxic molecules, Th1- and Th17-associated cytokines and chemokines, and immunoregulatory receptors. Single-cell analyses implicate inflammatory cytokine and antigen-presentation signals in the acquisition or maintenance of this state. High-resolution spatial profiling localised this programme predominantly to Th17 cells, which were preferentially enriched within multicellular inflammatory and tertiary lymphoid structure-associated niches. Across independent patient cohorts, a transcriptional signature derived from this state increased with endoscopic disease severity and was associated with reduced response to anti-TNF and anti-IL-12/23p40 therapies. Adoptive transfer of Gzma/Gzmb-deficient rather than wild-type CD4 T cells into Rag2-deficient recipient mice markedly attenuated experimental colitis and abrogated the polyfunctional cytokine phenotype, demonstrating that granzyme-dependent effector activity is a key mechanism driving CD4+ T-cell-mediated intestinal inflammation. Finally, human host-microbiome analysis linked this programme to intestinal dysbiosis, while transfer of dysbiotic microbiota promoted the emergence of a corresponding state in vivo. Collectively, these findings define a microbiota-responsive, spatially organised polyfunctional cytotoxic CD4 T-cell programme that contributes to intestinal inflammation and is associated with disease severity and treatment resistance in UC.

Broadly reactive antibodies elicited by SARS-CoV-2 infection or vaccination can reveal conserved viral vulnerabilities and inform vaccines with broad coronavirus coverage. Here, we characterize two human-derived monoclonal antibodies, B2014 and C5078, that recognize conserved epitopes on the SARS-CoV-2 RBD and retain activity across antigenically distinct variants. Notably, C5078 also recognizes diverse sarbecoviruses and remains active against currently circulating variants, including XFG and NB.1.8.1. Cryo-EM structures reveal that B2014 recognizes an epitope adjacent to the class 3 antibody site, whereas C5078 targets the highly conserved, cryptic site V epitope. Structural analysis defines how C5078 uses affinity-matured interactions to engage conserved RBD residues, providing a molecular basis for its exceptional breadth. Deep mutational scanning across multiple SARS-CoV-2 variant backgrounds further defines potential pathways of antibody escape, explaining the loss of B2014 activity against antigenically evolved variants while revealing a high barrier to escape from C5078. Together, these findings define distinct structural solutions for broad RBD recognition and highlight conserved, mutationally constrained epitopes that may serve as targets for vaccines designed to elicit antibody responses resilient to ongoing SARS-CoV-2 evolution and future sarbecovirus emergence.

Neutrophils are phenotypically heterogenous cells that mediate host defense and tissue homeostasis. Here, we identify emperipolesis - the evolutionarily conserved process by which neutrophils pass through megakaryocytes - as a phenotypically transformative route of egress from bone marrow. By intravital microscopy and 3-D histology, we show that the rapid form emperipolesis is markedly enhanced under inflammatory conditions. Neutrophils exit from megakaryocytes directly to the blood, acquiring exosomes enriched in proteins related to metabolism, migration, and immune function. This transfer induces a distinct neutrophil phenotype characterized by enhanced glycolysis, oxidative phosphorylation, cytokine release, and longevity. Correspondingly, emperipolesis-educated neutrophils display accelerated migration in vitro and in vivo. Disrupting emperipolesis does not alter circulating neutrophil abundance but impairs neutrophil infiltration into inflamed tissues, including Pseudomonas aeruginosa-infected lung. These findings establish emperipolesis as a mechanism by which megakaryocytes amplify neutrophil-mediated immunity.